Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 3298

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Therapeutic
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3298

License Grant
The Canadian Licensee holds a non-exclusive License from the Licensor for certain patent rights to develop and sub-License a specified polypeptide. The Licensee is obligated to make royalty payments after the first commercial sale of the polypeptide on a country by country basis on an aggregate worldwide scale of net sales.
License Property
The Licensor holds several patents involving IL-17E (also known as IL-25) is a recently identified cytokine that plays an important role in inflammation. Lorus has discovered that human IL-17E has potent anticancer properties against a range of solid tumors, including human melanoma, pancreatic, colon, lung, ovarian and breast tumor models with very low toxicity.
Field of Use
The Licensee has discovered that human IL-17E has potent anticancer properties against a range of solid tumors, including human melanoma, pancreatic, colon, lung, ovarian and breast tumor models with very low toxicity and have patents pending for the use of IL-17E in cancer in the major world markets.

IPSCIO Record ID: 332237

License Grant
Licensor hereby grants to Canadian Licensee and Licensee hereby accepts a non-exclusive license under Licensed Patents during the Term to research, develop, make (and have made), use, sell, offer for sale, and import Licensed Product in the Territory in the Field of Use.  Licensee shall have a right to grant sublicenses.
License Property
Licensed Patents shall mean (a) US Patent Nos. 6,579,520 and 6,569,645, (b) any patents issuing from continuations, divisions, or continuations-in-part from which any of the foregoing claim priority, and (c) invention certificates, substitutions, reissues, reexaminations, extensions, registrations, patent term extensions, supplementary, supplementary protection certificates, renewals and foreign counterparts of any of the foregoing (a) or (b), including without limitation EP 1240325, and CA 2391374.

6,579,520 – IL-17 related mammalian cytokine polypeptides (IL-17E)
6,569,645 – IL-17 homologous polypeptides and therapeutic uses thereof

Licensee Protein means a IL-17E protein for which either (a) the research and/or at least one Clinical Trial was significantly conducted by Licensee either on its own, or together and in
collaboration with a Sublicensee or (b) Licensee and/or its Sublicensees have exclusive marketing rights worldwide.

Field of Use
Field of Use means treatment of human cancer.

IPSCIO Record ID: 29247

License Grant
The Licensor granted an exclusive license to the patent, Tumor Radiosensitization Using Gene Therapy, for the prevention and treatment of all cancers except colon cancer, brain tumors and melanoma.
Field of Use
'Field' shall mean the prevention and treatment of all cancers except colon cancer, brain tumors and melanoma.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.